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2ABSTRACT 
The aim of this study was to develop and validate an analytical method to 
simultaneously determine European Union-regulated -lactams (penicillins and 
cephalosporins) and quinolones  in cow milk. The procedure involves a new solid phase 
extraction (SPE) to clean-up and pre-concentrate the three series of antibiotics before 
analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and ultra-
high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). 
LC-MS/MS and UPLC-MS/MS techniques were also compared. The method was 
validated according to the Directive 2002/657/EC and subsequently applied to 56 
samples of raw cow milk supplied by the Laboratori Interprofessional Lleter de 
Catalunya (ALLIC) (Laboratori Interprofessional Lleter de Catalunya, Control 
Laboratory Interprofessional of Milk of Catalunya ). 
Keywords: Antibiotics, milk, LC-MS/MS, UPLC-MS/MS, matrix effect, validation. 
31. INTRODUCTION 
Antibiotics are widely use in human and veterinary medicine. The -lactams, which 
include penicillins and cephalosporins, and quinolones, are the most frequently 
employed. These drugs are administered at therapeutic doses to treat bacterial infections 
in food-producing animals, such as cattle, swine, turkey and chicken. They are also used 
at sub-therapeutic doses as prophylactics or growth promoters, although European 
Union (EU) legislation has forbidden this practice since 2006 [1]. Milk is widely 
consumed globally and can contain antibiotics or their residues if the animals that 
produced it had been treated with the drugs. These residues might have direct toxic 
effects on consumers through allergic reactions or they may cause indirect problems by 
promoting bacterial resistance [2,3]. Thus, the use of antibiotics has become an 
increasingly important public health concern.  
The EU has established Maximum Residue Limits (MRLs) for several classes of 
antibiotics in animal products, such as milk and edible tissues, with the aim of 
minimising risk to human health [4-6]. In milk, the MRL ranges are between 4 and 30 
µg/kg for penicillins, 20 and 100 µg/kg for cephalosporins, and 30 and 100 µg/kg for 
quinolones.  
To enforce these regulations and ensure that consumers are protected from accidental 
consumption of contaminated milk, it is necessary to have strategies to regularly test 
large numbers of milk samples. Milk samples are usually examined by rapid screening 
methods that only indicate whether some antibiotics are present or not and also by 
immunoassays to determine the type of antibiotics [7]. This strategy is adequate to 
reduce the number of samples to be quantified and can be applied in routine laboratory 
4analysis. The samples that fail the screening tests are then examined using developed 
analytical methods that are sensitive enough to monitor and determine drugs in cow 
milk, thus allowing the identification and quantification of the antibiotic in accordance 
with EU regulations. 
There are several papers on antibiotic analysis in milk in the literature, but most focus 
on only few compounds or one class of antibiotics [10-15]. Although it is also possible 
to find multi-class published methods [8,16-24], some are not quantitative or do not 
determine the quality parameters necessary for validating the method according to 
European legislation [25]. Quinolones and penicillins regulated except AMOX and 
PENG, have been previously analysed in milk by ultra-high-performance liquid 
chromatography-time of flight-mass spectrometry (UPLC-TOF-MS) [19], while other 
authors [8] simultaneously measured the complete series of quinolones, penicillins and 
cephalosporins regulated by the EU in raw milk samples using UPLC with TOF to 
screen 150 veterinary drugs. 
Liquid chromatography (LC) coupled to several detectors have been used to analyse 
samples, although mass spectrometry (MS) detection has recently gained popularity 
since its selectivity and sensitivity enables the determination of drug residues in 
complex matrices [16,17,21,22,23]. An optimal method for routine analysis should 
allow rapid detection of a large number of compounds. In this sense, UPLC which uses 
small particle size columns and operates at a much higher pressure than LC, has been 
shown to be a promising solution for batch analysis. Compared to LC, UPLC improves 
resolution and sensitivity, as well as significantly reducing sample analysis time and 
mobile phase solvent consumption [8, 9, 19, 26, 27]. 
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The aim of this study was to develop a method for the multi-class and multi-residue 
determination of penicillins, cephalosporins and quinolones regulated by European 
legislation 37/2010 [5] in cow milk using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and ultra-high-performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS). The proposed method consisted of a new solid 
phase extraction (SPE) step to clean-up and pre-concentrate the three series of 
antibiotics simultaneously prior to analysis by liquid chromatography. The method was 
validated according to the Commission Decision 2002/657/EC [25] and subsequently 
applied to several milk samples from cows treated with antibiotics.  
62. EXPERIMENTAL PROCEDURES 
2.1 Reagents 
The standards were purchased from several pharmaceutical firms: 
Cephalosporins: cephalexin (LEX) and cefoperazone (PER) (Sigma, St. Louis, MO, 
USA), cephazolin (ZOL), cephapirin (PIR) and ceftiofur (TIO) (Fluka, Buchs, 
Switzerland), cefquinome (QUI) (AK Scientific, Inc., USA) and cephalonium (LON) 
was graciously provided by Schering-Plough Animal Health Corporation (Ireland). 
Penicillins: ampicillin (AMPI), dicloxacillin (DICL) and penicillin G (PENG) 
(European Pharmacopeia, Strasbourg Cedex, France), amoxicillin (AMOX), nafcillin 
(NAFC) and oxacillin (OXAC) (Sigma, St. Louis, MO, USA), and cloxacillin (CLOX) 
and piperacillin (PIPE; internal standard (IS)) (Fluka, Buchs, Switzerland). 
Quinolones: ciprofloxacin (CIP) (Ipsen Pharma, Barcelona, Spain), enrofloxacin (ENR) 
(Cenavisa, Reus, Spain), danofloxacin (DAN) (Pfizer, Karlsruhe, Germany), 
marbofloxacin (MAR) (Vetoquinol, Barcelona, Spain), flumequine (FLU) (Sigma, St. 
Louis, MO, USA) and pipemidic acid (PIP; internal standard (IS)) (Prodesfarma, 
Barcelona, Spain).  
All reagents were of analytical grade unless indicated. Formic acid (HFo), acetic acid 
(HAc), trifluoroacetic acid (TFA), acetonitrile (MeCN), methanol (MeOH), sodium 
dihydrogenphosphate and sodium hydroxide were supplied by Merck. Sodium chloride 
was supplied by Sigma. Ultrapure water was generated by a Milli-Q system (Millipore). 
7The solid phase extraction (SPE) cartridges were Oasis HLB (3 cm
3
/60 mg) obtained 
from Waters (Milford, MA, USA) and Strata X (1 cm
3
/30 mg; Phenomonex, USA). 
2.2 Standards and stock solutions 
Individual stock solutions of penicillins and cephalosporins were prepared at a 
concentration of 100 g/ml by dissolving in water. The individual stock solutions of 
quinolones were prepared at a concentration of 500 g/ml by dissolving in 50mM acetic 
acid aqueous solution (MAR, CIP, DAN and ENR). FLU at a concentration of 
100g/ml was prepared at a concentration of 100 g/ml in MeCN. 
The individual standard solutions of PIPE and PIP (IS) were prepared by dissolving the 
internal standards in water and 50mM acetic acid: MeCN (4:1, v/v) at a concentration of 
100 g/ml and 40 g/ml, respectively. The working individual standard solutions of IS 
were prepared at a concentration of 5 g/ml in Milli-Q water. 
Working solutions (containing a standard mixture for each family of antibiotics) were 
prepared at a concentration of 100MRL and 20MRL to validate the method.  For the 
preliminary studies, individual stock solutions were diluted to a concentration of 10 
g/ml in Milli-Q water. Working solutions were used to spike the milk samples. All 
standard solutions were stored at -20 ºC. 
Phosphate solutions 0.05M at pH 8.5 and 9, and 0.1M at pH 10 were prepared for 
addition to the milk samples. 
2.3 Instruments 
8Liquid chromatography separation was performed on a Zorbax Eclipse XDB-C8 
column (5m, 4.6 × 150 mm) from Agilent Technologies using a pre-column  Kromasil  
C8 (5m,  4.6 × 15 mm) supplied by Akady (Barcelona, Spain). The column used for 
separation by UPLC-MS/MS was an Acquity UPLC BEH Shield RP 18 (1.7 m, 2.1 × 
50 mm) from Waters (Ireland). 
An HP Agilent Technologies 1100 LC system equipped with an autosampler and 
coupled to an API 3000 triple-quadrupole mass spectrometer (PE Sciex) with a turbo 
ionspray source was used. The system was controlled by the Analyst v.1.4.2 software 
from Applied Biosystems (Foster City, CA, USA). 
Chromatographic analysis by UPLC was performed using Acquity-Ultra Performance 
LC- Waters system equipped with an autosampler. The mass spectrometer was the same 
as that used by LC. The system was controlled by the Analyst v.1.4.2 software from 
Applied Biosystems (Foster City, CA, USA) and the Acquity Console to control the 
UPLC.  
A Crison 2002 potentiometer (± 0.1 mV) (Crison, Barcelona, Spain) using a Crison 
5203 combined pH electrode from Orion Research (Boston, MA, USA) was used to 
measure the pH of the phosphate solution and of the mobile phase. The electrode was 
stored in water when not used and soaked for 15 to 20 min in a MeCN-water mixture 
(15%) before pH measurements of the mobile phase. 
A Rotanta 460RS (Hettich Zentrifuguen) centrifuge was used to perform the extraction. 
The SPE step was carried out on a Supelco vacuum manifold with 12 cartridges and a 
Supelco vacuum manifold with disposable liners for 24 cartridges (Bellefonte, PA, 
9USA) connected to a Supelco vacuum tank. Evaporation to dryness was performed 
under a stream of nitrogen at the end of sample treatment. 
2.4 Procedure 
2.4.1 Sample treatment and clean-up (SPE) 
To achieve a single method valid for analysing the three families of antibiotics, different 
methods from the literature were tested. 
Method 1  
The following method was based on an article of Becker [17] with some modifications. 
Raw milk samples were used to optimise and validate the method. Specific volumes of 
antibiotic working solutions were added to 2.0 g of whole milk to give appropriate 
concentration of each antibiotic. The IS, PIPE and PIP were added at a concentration of 
100 g/kg. 
After vortexing for 1 min, the milk samples were kept at room temperature for 10 min 
and centrifuged (1500 g ×10 min). MeCN was added (to defat milk) to obtain a final 
volume of 15 ml and the samples were vortexed for 15s. After the solutions were 
centrifuged (1500 g ×15 min), the supernatants were transferred into tubes. 
4 mL of a saturated sodium chloride solution was added to avoid foaming during the 
MeCN evaporation. MeCN was evaporated completely under a stream of nitrogen and 
then mixed with 15 ml of 0.05 M phosphate solution at pH 9 to obtain a pH from 8.5 to 
8.7, depending on the milk sample used. 
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Oasis HLB cartridges were used and pre-conditioned with 2 mL of methanol, 2 mL of 
water and 2 mL of 0.05 M phosphate solution at pH 8.5. The samples were passed 
through the cartridge. The clean-up solution was 3 mL of phosphate solution at pH 8.5, 
1 mL water and 1 mL 3% MeCN: H2O in order to decrease matrix interference. The 
analytes were eluted with 3 mL of MeCN:MeOH:H2O (30:40:30, v:v:v). 
The elution fraction obtained from SPE was evaporated to dryness under a stream of 
nitrogen. 200 l of water were added to dissolve the residue to be injected into the LC 
system. 
Method 2  
This method was used previously to determine penicillin levels in milk [10]. In 
summary, the extraction method involved addition of 0.5 mL of phosphate solution 0.1 
M at pH 10, centrifugation of samples and an SPE process using HLB cartridges. The 
HLB cartridges were activated with 1 mL of methanol, 1 mL of water and 1 mL of 0.1 
M phosphate solution at pH 10. After samples were passed through the system, the 
cartridge was cleaned with 3 mL of water to decrease matrix interference. The analytes 
were eluted with 2 mL of methanol. 
Method 3  
This method was previously applied to test quinolones [11]. The extraction procedure 
consisted of adding 2 mL of Milli-Q water to fortified milk samples and subsequent 
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application of solid phase extraction on a Strata X cartridge. The cartridges were 
conditioned by passing 2 mL of MeOH and 2 mL of Milli-Q water. In the washing step, 
the clean-up solutions and order of addition were as follows: 1 mL of Milli-Q water, 1 
mL of 0.5% TFA:MeOH (9:1, v/v), 1 mL of Milli-Q water, 1 mL of 1% TFA:MeCN 
(9:1, v/v) and finally, 1 mL of Milli-Q water. The analytes were eluted using 2 ml of 1% 
TFA:MeCN (25:75, v/v). 
Method 4  
This method was a mix of the three methods described above and consisted of weighing 
2 g of sample and adding appropriate volumes of antibiotic working solutions. After 
vortexing for 1 min, the milk samples were kept at room temperature for 10 min and 
centrifuged (1500 g ×10 min). The defatted milk was mixed with 15 ml of 0.05 M 
phosphate solution at pH 9. 
The Oasis HLB cartridges were preconditioned with 2 mL of methanol, 2 ml of water 
and 2 mL of 0.05 M phosphate solution at pH 8.5. The samples were loaded onto the 
cartridge. The clean-up solution was 3 mL of phosphate solution at pH 8.5, 1 mL of 
water and 1 mL of 3% MeCN:H2O. The analytes were eluted with 3 mL of 
MeCN:MeOH:H2O (30:40:30, v:v:v). 
The elution fraction obtained from SPE was evaporated to dryness under a stream of 
nitrogen. 200 l of water were added to dissolve the residue to be injected into the LC 
system. 
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2.4.2 Chromatographic conditions 
The mobile phase of LC-MS/MS was composed of water and MeCN with 0.1% formic 
acid in both solvents. The initial mobile phase was composed of H2O:MeCN (85:15, 
v/v) with a pH of 3.2. The flow-rate was 1 mL/min.  In the case of UPLC-MS/MS, the 
mobile phase and flow used were the same as those for LC but the initial mobile phase 
consisted of H2O:MeCN (88:12, v/v).  
Table 1 shows the gradient used for the separation of analytes in LC and UPLC. 20 l 
aliquots of the extracts were injected into the LC-MS while 6 l aliquots of the filtered 
extracts were injected into the UPLC. 
2.4.3. LC-ESI-MS/MS parameters 
The LC-ESI-MS/MS conditions were optimised by individual direct injection of each 
compound at a concentration of 10µg/ml and a flow-rate of 0.05 ml/min. The turbo ion 
spray source was in positive mode with the following settings: capillary voltage 4500V, 
nebuliser gas (N2) 10 (arbitrary units), curtain gas (N2) 12 (arbitrary units) and drying 
gas (N2) was heated to 400 ºC and introduced at a flow-rate of 6500 ml/min. Table 2 
shows the declustering potential (DP), focusing potential (FP) and entrance potential 
(EP) optimised to detect compounds with higher signals. 
Multiple reaction monitoring (MRM) experiments in the positive ionisation mode were 
performed using a dwell time of 60 ms. The ions in the MRM mode were produced by 
collision-activated dissociation (CAD) of selected precursor ions in the collision cell of 
the triple quadrupole and analysed with the second analyser of the instrument. N2 4 
(arbitrary units) was used in CAD. Two transitions were followed for each analyte, one 
was used for quantification and the other for identification. Table 2 also shows these 
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transitions with their optimum collision energy. For UPLC-MS/MS, a dwell time of 40 
ms was used to detect all the analytes. 
2.5 Quality parameters 
The validation of the method was carried out using spiked raw milk samples. The 
quality parameters established were linearity range, recovery, precision, selectivity, 
decision limit (CC), detection capability (CC), limit of detection (LOD) and limit of  
quantification (LOQ) according to the EU regulation 2002/657/EC [25] and the Food 
and Drug Administration (FDA) guideline for bioanalytical assay procedure [6].   
The linearity was tested from the calibration curves prepared from spiked milk samples 
at a concentration ranging from the LOQ of each analyte and 3MRL. Each level was 
prepared in duplicate. PIPE and PIP were the internal standards used at a concentration 
of 100 µg/kg. The calibration curves were constructed using analyte/internal standard 
peak area ratio versus concentration of analyte/internal standard ratio. 
The limit of detection (LOD) is the lowest concentration of analyte that the analytical 
process can reliably differentiate from background levels, while the limit of 
quantification (LOQ) is the lowest concentration of analyte that can be quantified. 
These were determined using spiked milk samples at different concentrations from 
0.001 MRL to 0.1MRL and were prepared in duplicate. LOD and LOQ values were 
calculated from a signal-to-noise ratio (S/N) of 3 and 10, respectively.  
Recovery experiments were performed by comparing the results for extracted standard 
samples of milk and internal standards added before the extraction procedure with the 
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non-extracted standards prepared at the same concentrations in blank extracts 
representing 100 % recovery. The concentration range was from LOQ and 3 MRL for 
each compound. 
Intra-day precision was assessed by comparing the results of five replicates prepared the 
same day at three different concentrations (0.5 MRL, MRL and 2 MRL). The procedure 
was repeated to determine inter-day precision by comparing results from samples 
prepared and analysed on three different days. The relative standard deviations (%RSD) 
were calculated.  
The decision limit (CC) is the limit at and above which it can be concluded with an 
error probability of  that a sample is non-compliant. Detection capability (CC) means 
the smallest content of a compound that may be detected, identified and/or quantified in 
a sample with an error probability of  [25,28]. CC values were determined by 
analysing 20 blank samples fortified with quinolones, penicillins and cephalosporins at 
MRL concentrations. CC was calculated as the decision limit CC plus 1.64 times the 
corresponding standard deviation ( = 5%), supposing that the standard deviation at the 
MRL is similar to that obtained at the CC level. 
2.6 Matrix Effect 
Matrix effect was evaluated by preparing standard solutions of analytes studied and 
solutions of analytes in milk. Milk from four different batches was used to evaluate the 
matrix effect. Aliquots of the corresponding milk were subjected to SPE and the 
extracts obtained were spiked separately with PENG, PIPE and PIP. Ten replicates were 
prepared of each batch of milk. Ten standard solutions of PENG, PIPE and PIP were 
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prepared in water at the same concentration as the matrix-matched solutions. All 
samples were analysed by LC and UPLC.   
2.7 Positive samples  
56 samples that tested positive in the screening test were obtained from the “Control 
Laboratori Interprofessional Lleter de Catalunya (ALLIC)” in different batches. The 
effectiveness of the developed method was checked by analysing the samples with the 
M2 method. The samples were labelled as M1 to M56. The samples were assessed in 
duplicate when there were sufficient amounts. 
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3. RESULTS AND DISCUSSION  
3.1 Optimisation of the LC conditions 
Co-eluting compounds originating from the matrix can enhance or suppress signals. 
When analytes and matrix compounds enter the ion source simultaneously, the 
ionisation efficiency of the analyte might be affected. Therefore, improvements in 
chromatographic separation, complete separation of analytes is not required in MS/MS 
detection, could result in decreased amounts of matrix compounds co-eluting with the 
analyte and thus, reduce the matrix effect. Consequently, chromatographic gradient 
conditions were adjusted to keep chromatographic run times as short as possible and 
also to achieve nearly complete separation of all analytes. The optimised LC conditions 
are described in section 2.4.3. Figure 1 shows the separation of the antibiotics at their 
MRL levels by LC and UPLC. As shown in Figure 1A, LC-MS/MS separated 
penicillins, cephalosporins and quinolones in less than 10 minutes. To use UPLC, the 
LC gradient was modified by a gradient converter software included in the UPLC 
system. The change of the gradient was necessary as the column and working pressure 
of the equipments were different. With the new gradient, analysis of the 21 drugs was 
achieved in less than 4 minutes (Figure 1B). 
3.2 Preliminary study 
In this study, commercial whole milk samples were used to test the four methods 
described above. This milk was used because it was easier to obtain and also contained 
less fat than raw milk and, therefore, easier to treat. The results of the study are given in 
Figure 2. Method 1(M1) had very high recoveries for most of the analytes, but too low 
for AMOX, AMPI, CIP and LEX. Moreover, its results were scattered. With method 3 
(M3) using an acidic medium, some analytes were not observed, possibly due to 
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degradation.  It was a fast method, but the recoveries of cephalosporins were lower than 
those obtained with method 2 (M2). Method 4 (M4) had intermediate recoveries, but the 
recovery was only around 20% for AMOX. Furthermore, the elution solution had a 
large percentage of water (30%), making the evaporation slower and the method very 
long. The best method was M2 and although it did not elicit the best recoveries for 
penicillins, these recoveries were still quite good. In addition, the best results for 
AMOX and LEX were obtained by this method. 
3.3 Optimisation of the extraction method 
Some experiments using M2 were performed to confirm whether commercial and raw 
milk samples gave similar results. The recoveries were similar for most of the analytes, 
but there were noticeable differences (~40%) in compounds like DICL, PIR, CIP and 
ENR. As a consequence, the following studies were carried out using raw milk.  
The evaporation step was also optimised. Air and nitrogen were tested and the 
recoveries obtained for quinolones and penicillins were similar for both. However, 
using nitrogen as the drying gas gave better results for cephalosporins, where 
differences higher than 20% were obtained for LON and ZOL.  
3.4 Matrix effect 
Some researchers have focused on optimising sample preparation to reduce matrix 
effect, while others have assessed the level of matrix effect and compensated for the 
alteration in signal by using an internal standard (IS), often a stable isotope-labelled 
analogue of the drug [29-32] or, if it is lacking, a structural analogue. However, in a 
multi-component analysis, finding an appropriate IS for every analyte might be difficult 
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or impossible. In this study, two IS were chosen to correct for matrix effect: PIPE and 
PIP. PIPE was chosen as an IS for the quantification of β-lactams (cephalosporins and 
penicillins), while PIP was chosen as the IS for quantifying quinolones. 
During the quantification of -lactams (penicillins and cephalosporins) by UPLC-
MS/MS, some inconsistencies were observed in the calibration curves, where linear 
correlation between the analyte/IS (PIPE) areas and the concentration ratio was only 
good for PENG. There were no such problems with LC-MS/MS analysis since 
chromatographic separation was different from that of UPLC and there were no matrix 
components co-eluting with the analytes that could suppress the ions. Regarding the 
analyte signal for PENG and its IS (PIPE), there was poor reproducibility of the signal 
and either ion suppression. 
All data from -lactams were treated without using the IS (PIPE) and a significant 
increase in the linearity of the calibration curves was observed, except for PENG, where 
linearity did not improve. Unfortunately, this did not give satisfactory precision. These 
results are not surprising given the lack of an IS, which plays a very important role in 
compensating for variation resulting from samples, instrument, manipulation or matrix 
effect. The β-lactams were analysed with PIP as the IS, which significantly increased 
the linearity of the calibration curves of all -lactams except PENG.   
Possible matrix effect on the signals for PIPE (IS) and PENG were evaluated by 
studying the difference between the mass spectrometric signal for PIPE and PENG in 
standard solution and the signal for these compounds in a biological matrix, such as 
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milk. Milk from four different batches was used to evaluate the matrix effect, using the 
same samples for LC and UPLC.  
Figure 3 shows the normalised area for PIPE and PENG for samples analysed by LC-
MS/MS (Figure 3A) and UPLC-MS/MS (Figure 3B). The areas for PIPE and PENG in 
milk and standard solutions obtained by LC-MS/MS did not show significant 
differences. However, the areas for PIPE and PENG were very much lower in milk 
samples than in standard solutions for UPLC-MS/MS analysis. These differences could 
be attributed to the matrix effect, which can be calculated using the modified version of 
the equation described by Matuszewki [32,33]: 
100x1)
A
A
(EffectMatrix%
solutionstandard
milk
−=
where Amilk is the area for the analyte in milk and Astandard solution is the area for the 
compound in standard solution. Therefore, around 80% matrix effect was observed for 
PENG and PIPE with UPLC. However, the same evaluation performed with PIP did not 
show any ion suppression. Thus, PIP was used to quantify -lactams undergoing UPLC. 
PIPE and PENG have similar retention times in UPLC. We think that their matrix effect 
are compensated and for this reason PENG is the only -lactam that offers a good 
linearity in its quantification when PIPE is used as IS. 
No matrix effect was observed for LC and subsequently, -lactam quantification was 
conducted using PIPE as the internal standard instead of PIP. 
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3.5 Method validation 
The optimised extraction method was validated for penicillins, cephalosporins and 
quinolones according to the European Union regulation 2002/657/EC [25] and the FDA 
guideline for bioanalytical assay procedure [6]. 
3.5.1 Linearity range 
Linearity was evaluated using calibration curves (prepared in blank milk spiked with 
antibiotics before SPE ) where the relationships between peak area and concentration 
are represented. Due to the problems observed for PIPE in UPLC, PIP was used as the 
IS for all analytes except PENG. In LC, no problems were found with PIPE, which was 
therefore used as the IS for β-lactams, while PIP was used for quinolones.  As shown in 
Tables 3, 4 and 5 for cephalosporins, penicillins and quinolones, respectively, all 
compounds presented good linearity in the concentration range studied (from 0.1 to 3 
MRL) with a correlation coefficient higher than 0.990 for both LC and UPLC. 
3.5.2 LOD and LOQ 
LOD and LOQ values were determined in milk samples spiked at different levels, 
taking signal-to-noise ratios of 3 and 10, respectively. As displayed in Tables 3, 4 and 5, 
LOD values ranged from 0.03 to 0.5 µg/kg and LOQ values from 0.1 to 1.25 µg/kg 
using LC. On the other hand, with UPLC, the range of LOD was 0.02 to 0.75 µg/kg and 
0.1 to 2.5 µg/kg for LOQ, except for DICL, which had a high LOQ value of 9 µg/kg. 
This high value could be because DICL was the last compound to be eluted and a 
broadening peak was obtained. In any case, the results obtained were always lower than 
the MRLs. 
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3.5.3 Accuracy  
The accuracy of the method was assessed by a recovery test. The recovery of the 
different compounds was calculated by calibration and external curve comparison. In 
Tables 3, 4 and 5, the results for all antibiotics are shown with their associated standard 
desviation (SD). All drugs analysed by LC-MS/MS had recoveries higher than 70% 
with the exception of AMOX (55%), ENR (68%) and DAN (39%). When drugs were 
evaluated by UPLC-MS/MS, the recoveries were higher than 75% except for AMOX 
(52%) and DAN (49%). 
3.5.4 CC and CC    
The revised criteria of 657/2002/EC [25] introduced CC and CC to replace the LOD 
and LOQ, respectively. These parameters were established for each compound at their 
MRL. Tables 3, 4 and 5 show CC values with an error of 5% (probability of false non-
compliance 5%) and CC values with an error of  = 5% (probability of false 
compliance 5%). Comparable results were obtained for drugs screened by LC-MS/MS 
and UPLC-MS/MS. 
3.5.5 Precision studies 
The precision of the method was evaluated in terms of repeatability (same day – intra-
day precision) and intermediate precision (different days – inter-day precision). The 
intra-day and inter-day precision of the methods were evaluated at three concentrations. 
To quantify the concentration of samples, the calibration curves were used. The 
repeatability values expressed as RSD % were lower than 15%, which is within the 
acceptance criteria of the FDA [6] for validating analytical methods (Tables 3, 4 and 5). 
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3.5.6 Applicability of the method  
56 samples from animals treated with β-lactams or quinolones were studied. The 
samples were analysed in duplicate when there were sufficient amounts. To see if the 
LC-MS/MS and UPLC-MS/MS techniques were comparable, 12 samples were analysed 
using both techniques. Table 6 shows the results of these samples.  The results obtained 
with the two techniques were similar except for M9, a sample that contained AMOX 
(6.2 µg/kg) that was non-compliant with UPLC (CC  5.4 µg/kg), while the value 
found (4.8 µg/kg) is compliant with LC (CC 6 µg/kg). Since both LC and UPLC 
detected similar concentrations of antibiotics in the 12 samples evaluated, the remaining 
samples were only analysed by one of the techniques. Table 7 gives the results of the 
rest of the samples analysed by LC-MS/MS or UPLC-MS/MS. As seen in Tables 6 and 
7, all the milk samples contained at least one antibiotic, while residues of more than one 
antibiotic from the same or different families were found in 8 samples, indicating 
multiple uses of -lactams and quinolones. Five samples, M21, M22, M49, M54 and 
M55, were found positive for the quinolones ENR and its metabolite CIP.  
Among all the samples, 38 were found to be fit for human consumption, according to 
European Union regulation (Tables 6 and 7). Only 18 samples were considered non-
compliant with current EU legislation, having an error probability of  because the 
concentration calculated in these samples were higher than the CC values determined 
previously. AMOX, PENG and PIR were the most common drugs found in the 56 
samples. 39% of the non-complaint samples contained AMOX and 44% had PENG.   
Figure 4 illustrates, as an example, the chromatogram obtained for a sample positive for 
PENG by LC-MS/MS and UPLC-MS/MS. The sample contained a high concentration 
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(19µg/kg) of this penicillin and was non-compliant (CC  5µg/kg), thus not fit for 
human consumption. 
Figures 5 and 6 show chromatograms of samples M35 and M55 analysed by only one of 
the techniques studied and with the corresponding confirmatory chromatogram. Both 
samples were considered compliant because their residue concentrations were lower 
than the calculated CC. Figure 5 shows the results of a sample containing 22.5 µg/kg of 
the cephalosporin PIR, while Figure 6 gives the results of a sample containing 3.5 µg/kg 
of PIR and 7.4 µg/kg of ENR. The metabolite of ENR, CIP, was also found at a higher 
concentration (28 µg/kg) than that of its parent compound, demonstrating that ENR is 
metabolized mostly into CIP. However, the concentration detected was lower than the 
EU-regulated MRL.  
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CONCLUSIONS 
A multi-class, multi-residue method was developed and validated for the simultaneous 
determination of 19 antibiotics regulated by the European legislation 37/2010/EC in raw 
cow milk using LC-MS/MS and UPLC-MS/MS. The method simultaneously detected 
substances from three families of antibiotics with acceptable quality parameters. The 
recoveries of the antibiotics were higher than 70%, except for AMOX and DAN. The 
LOD and LOQ values were lower than the established MRLs and the other parameters 
were also in accordance with European regulation. UPLC technology demonstrated 
significant advantages with respect to speed, sensitivity and resolution, making it an 
attractive option for the analysis of antibiotics in milk. However, the fast gradient used 
in UPLC promoted matrix effects by reducing chromatographic separation between 
analytes and endogenous milk compounds. Among all the samples analysed (56 real 
positive samples provided by the “Laboratori Interprofessional Lleter de Catalunya” 
(ALLIC) Barcelona, Spain), 38 of them (~70%) were found to be fit for human 
consumption. AMOX and PENG were the most common residues found. 39% of the 
non-complaint samples contained AMOX and 44% contained PENG. 
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FIGURE CAPTIONS 
Figure 1. Chromatogram obtained from a milk sample fortified at the MRL level using: 
A) LC-MS/MS B) UPLC-MS/MS.  
Peaks: 1) AMOX, 2) PIR, 3) QUI, 4) PIP, 5) MAR, 6) AMPI, 7) EX, 8) LON, 9) CIP, 
10) DAN, 11) ENR, 12) ZOL, 13) PER, 14) TIO, 15) PIPE, 16) PENG, 17) FLU, 18) 
OXAC, 19) CLOX, 20) NAFC and 21) DICL. 
Figure 2. Recoveries obtained by application of the different methods tested. Study 
made with commercial milk.  
Figure 3. Matrix effect on the response of PIPE and PENG in milk using: A) LC-
MS/MS and B) UPLC-MS/MS.  
Figure 4. Chromatograms obtained for a non compliant sample of raw milk in PENG by 
LC-MS/MS and UPLC-MS/MS.  
Figure 5. Chromatogram obtained for a positive sample of raw milk in PIR by LC-
MS/MS. 
Figure 6. Chromatogram obtained for a positive sample of raw milk in PIR and ENR by 
UPLC-MS/MS. 
Table 1. Gradients used for the separation of the substances studied by LC and UPLC 
LC-MS/MS   
time (min) % A % B 
0 15 85 
2.0 15 85 
4.0 45 55 
7.0 56 44 
8.5 56 44 
10 15 85 
11 15 85 
UPLC-MS/MS   
0 12 88 
0.28 12 88 
2.36 45 55 
3.06 45 55 
3.40 12 88 
3.64 12 88 
Table 2. [M+H]
+
 ions, optimised parameters of the mass spectrometer and quantification and 
identification transitions for the substances studied and their optimum collision energy. 
 M/z SIM (Q1Multiple ions/Q1) 
Transition 
Quantification 
(CE)* 
Transition 
Identification 
(CE) 
  IS DP FP EP   
AMOX 366 4500 40 150 6 366  114 (28) 366  208 (19)
AMPI 350 4500 65 150 6 350  106 (26) 350  192 (21)
CLOX 436 4500 40 140 7 436  160 (20) 436  277 (20)
DICL 470 4500 50 150 8 470  160 (21) 470  311 (22)
NAFC 415 4500 50 120 9 415  199 (19) 415  256 (21)
OXAC 402 4500 40 160 9 402  160 (18) 402  243 (18)
PENG 335 4500 40 150 7 335  160 (16) 335  176 (16)
PIPE(IS) 518 4500 40 175 5 518  143 (27) 518  160 (16)
PIR 424 4500 40 150 5 424  292 (20) 424  181 (35)
QUI 529 4500 40 175 5 529  134 (20) 529  396 (20)
LEX 348 4500 30 125 5 348  140 (35) 348  158 (15)
LON 459 4500 30 125 5 459  152 (30) 459  337 (20)
ZOL 455 4500 40 175 5 455  323 (15) 455  295 (25)
PER 646 4500 50 200 11 646  290 (35) 646  530 (20)
TIO 524 4500 50 200 5 524  285 (30) 524  241 (25)
MAR 363 4500 45 200 10 363  320 (22) 363  345 (30)
CIP 332 4500 45 200 10 332  314 (32) 332  288 (27)
DAN 358 4500 45 200 10 358  340 (31) 358  283 (31)
ENR 360 4500 45 200 10 360  316 (29) 360  342 (29)
FLU 262 4500 38 200 10 262  244 (26) 262  202 (45)
PIP(IS) 304 4500 50 200 10 304  286 (30) 304  261 (25)
*CE Collision energy (V) 
Table 6. Analysis of positive milk samples by LC-MS/MS and UPLC-MS/MS. 
  Concentration (µg/kg) 
 Antibiotic 
found 
LC-MS/MS UPLC-MS/MS 
M1 AMOX, PER 1.3 (0.1), 39 (4) 1.1 (0.1), 55 (8) 
M2 PENG 5.9 (0.2) 6.9 (0.7) 
M3 AMOX 1.2 (0.2) 1.2 (0.4) 
M4 AMOX 7.0 (0.2) 7.1 (0.2) 
M5 PENG 19.0 (0.3) 20.0 (0.1) 
M6 PENG 14.0 (0.4) 14.0 (0.1) 
M7 PENG 29.0 (0.3) 28 (2) 
M8 AMOX 3.0 (0.5) 3.2 (0.5) 
M9 AMOX 4.8 (0.6) 6.2 (1.8) 
M10 LEX 36 (12) 37 (18) 
M11 LEX 66 (4) 60 (13) 
M12 LEX 128 (15) 136 (41) 
Table 7. Samples of milk analysed by LC-MS/MS or UPLC-MS/MS. 
LC-MS/MS 
 Antibiotic found Concentration (µg/kg). 
M13 AMOX 7 (2) 
M14 AMOX 4.7 
M15 AMOX 46 
M16 CLOX, LON 51.5 (0.9), 4.4(0.2) 
M17 PIR 11.3 (0.7) 
M18 PENG 3.5 (0.4) 
M19 PIR 7.5 (0.8) 
M20 AMPI, DICL 2.9 (0.3), 2.5 (0.2) 
M21 ENR, CIP 11.1 (0.1), 22.7 (0.9) 
M22 ENR, CIP 11.3 (0.4), 24.1(0.5) 
M23 PIR 6.3 (0.6) 
M24 PIR 5.6 (0.2) 
M25 PIR 8.4 (0.6) 
M26 PENG 4.1 (0.3) 
M27 PIR 8.0 (0.4) 
M28 PENG 1.6 (0.0) 
M29 AMOX 19.0 (4.0) 
M30 AMOX 10.0 (0.7) 
M31 AMPI, DICL 5.95 (0.02), 6.2 (0.4) 
M32 AMOX, PER 6.5 (1.3), 7.7 (0.4) 
M33 PIR 9.6 
M34 PENG 6.5 
M35 PIR 22.5 (0.8) 
M36 PENG 0.95 (0.05) 
M37 PENG 3.7 (0.2) 
M38 PIR 15 (2) 
M39 PENG 3.4 (0.6) 
M40 PENG 2.7 (0.2) 
M41 PENG 3.8 (0.2) 
M42 PENG 3.8 (0.2) 
M43 PENG 3.5 (0.1) 
M44 PENG 5.1 (0.1) 
M45 AMOX 1.9 (0.4) 
M46 PENG 14.5 
M47 PENG 13 (2) 
M48 AMOX 42 (4) 
   
UPLC-MS/MS 
M49 PIR, ENR, CIP 5.1, 4.8, 7.6 
M50 AMOX 2.1 (0.3) 
M51 PENG 3.3 (0.5) 
M52 PIR 3.6 (0.4) 
M53 AMPI, CLOX 2.6 (0.2), 17.7 (0.9) 
M54 ENR, CIP 3.5 (0.1), 18 (2) 
M55 PIR, ENR, CIP 3.5 (0.6), 7.4 (0.3), 28(2) 
M56 PENG 1.2 (0.1) 
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